Paul W. Scorer

Cambridge, ENG CB101XL, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Next-generation sequencing-based evaluation of the actionable landscape of genomic alterations in solid tumors: the "MOZART" prospective observational study.

Next-generation sequencing-based evaluation of the actionable landscape of genomic alterations in solid tumors: the "MOZART" prospective observational study.

Journal: The oncologist

Published: February 18, 2024

Impact of Decalcification, Cold Ischemia, and Deglycosylation on Performance of Programmed Cell Death Ligand-1 Antibodies With Different Binding Epitopes: Comparison of 7 Clones.

Impact of Decalcification, Cold Ischemia, and Deglycosylation on Performance of Programmed Cell Death Ligand-1 Antibodies With Different Binding Epitopes: Comparison of 7 Clones.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: January 09, 2023

Correction: Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies.

Correction: Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: October 24, 2019

Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies.

Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: May 17, 2019

Interobserver Reliability of Programmed Cell Death Ligand-1 Scoring Using the VENTANA PD-L1 (SP263) Assay in NSCLC.

Interobserver Reliability of Programmed Cell Death Ligand-1 Scoring Using the VENTANA PD-L1 (SP263) Assay in NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: May 17, 2019

Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma.

Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma.

Journal: Diagnostic pathology

Published: January 24, 2019

Assessment of PD-L1 mRNA and protein expression in non-small cell lung cancer, head and neck squamous cell carcinoma and urothelial carcinoma tissue specimens using RNAScope and immunohistochemistry.

Assessment of PD-L1 mRNA and protein expression in non-small cell lung cancer, head and neck squamous cell carcinoma and urothelial carcinoma tissue specimens using RNAScope and immunohistochemistry.

Journal: PloS one

Published: December 11, 2018

Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay.

Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay.

Journal: Diagnostic pathology

Published: January 19, 2018

Correction to: Abstracts : 29th European Congress of Pathology.

Correction to: Abstracts : 29th European Congress of Pathology.

Journal: Virchows Archiv : an international journal of pathology

Published: December 03, 2017

Relevance of deep learning to facilitate the diagnosis of HER2 status in breast cancer.

Relevance of deep learning to facilitate the diagnosis of HER2 status in breast cancer.

Journal: Scientific reports

Published: January 10, 2017

Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer.

Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 23, 2016

Showing 1-11 of 11

Last Updated: 09/26/2026